MX2022013904A - Tratamiento de trastornos de adaptacion. - Google Patents
Tratamiento de trastornos de adaptacion.Info
- Publication number
- MX2022013904A MX2022013904A MX2022013904A MX2022013904A MX2022013904A MX 2022013904 A MX2022013904 A MX 2022013904A MX 2022013904 A MX2022013904 A MX 2022013904A MX 2022013904 A MX2022013904 A MX 2022013904A MX 2022013904 A MX2022013904 A MX 2022013904A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- androsta
- dien
- effective amount
- therapeutically effective
- Prior art date
Links
- 208000012826 adjustment disease Diseases 0.000 title abstract 2
- 206010001296 Adjustment disorder with anxiety Diseases 0.000 abstract 3
- -1 androsta-4,16-dien-3-ol steroid Chemical class 0.000 abstract 2
- NYVFCEPOUVGTNP-FZFXZXLVSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound OC1CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC2=C1 NYVFCEPOUVGTNP-FZFXZXLVSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a métodos para tratar trastornos de adaptación, en particular el trastorno de adaptación con ansiedad (AjDA), en un individuo que incluye la etapa de administrar una cantidad terapéuticamente eficaz de un esteroide androsta-4,16-dien-3-ol al individuo. En algunas modalidades de los métodos, se administra a un paciente una cantidad terapéuticamente eficaz de esteroide androsta-4,16-dien-3-ol, y en algunas modalidades de las composiciones, se incluye una cantidad terapéuticamente eficaz de androsta-4,16-dien-3-ol en una composición farmacéutica para el tratamiento de AjDA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026441P | 2020-05-18 | 2020-05-18 | |
| PCT/US2021/032920 WO2021236606A1 (en) | 2020-05-18 | 2021-05-18 | Treatment of adjustment disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013904A true MX2022013904A (es) | 2023-01-04 |
Family
ID=78707532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013904A MX2022013904A (es) | 2020-05-18 | 2021-05-18 | Tratamiento de trastornos de adaptacion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210867A1 (es) |
| EP (1) | EP4153182A4 (es) |
| JP (1) | JP2023527288A (es) |
| KR (1) | KR20230031214A (es) |
| CN (1) | CN115697346A (es) |
| AU (1) | AU2021277216A1 (es) |
| BR (1) | BR112022023428A2 (es) |
| CA (1) | CA3178758A1 (es) |
| IL (1) | IL298185A (es) |
| MX (1) | MX2022013904A (es) |
| WO (1) | WO2021236606A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA57706C2 (uk) * | 1995-06-06 | 2003-07-15 | Косенсіз, Інк | Нейроактивні стероїди ряду андростанів та прегнанів, фармацевтична композиція і спосіб лікування (варіанти) |
| US8309539B2 (en) * | 2005-09-09 | 2012-11-13 | Pherin Pharmaceuticals, Inc. | Acute treatment of social phobia |
| AU2008265898B2 (en) * | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
-
2021
- 2021-05-18 BR BR112022023428A patent/BR112022023428A2/pt unknown
- 2021-05-18 US US17/998,823 patent/US20230210867A1/en active Pending
- 2021-05-18 AU AU2021277216A patent/AU2021277216A1/en active Pending
- 2021-05-18 CA CA3178758A patent/CA3178758A1/en active Pending
- 2021-05-18 MX MX2022013904A patent/MX2022013904A/es unknown
- 2021-05-18 JP JP2022570402A patent/JP2023527288A/ja active Pending
- 2021-05-18 IL IL298185A patent/IL298185A/en unknown
- 2021-05-18 CN CN202180036436.4A patent/CN115697346A/zh active Pending
- 2021-05-18 WO PCT/US2021/032920 patent/WO2021236606A1/en unknown
- 2021-05-18 EP EP21809566.9A patent/EP4153182A4/en active Pending
- 2021-05-18 KR KR1020227044236A patent/KR20230031214A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022023428A2 (pt) | 2023-01-17 |
| JP2023527288A (ja) | 2023-06-28 |
| WO2021236606A1 (en) | 2021-11-25 |
| CN115697346A (zh) | 2023-02-03 |
| EP4153182A1 (en) | 2023-03-29 |
| US20230210867A1 (en) | 2023-07-06 |
| IL298185A (en) | 2023-01-01 |
| AU2021277216A1 (en) | 2022-12-15 |
| EP4153182A4 (en) | 2024-05-29 |
| CA3178758A1 (en) | 2021-11-25 |
| KR20230031214A (ko) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| Brahmkshatriya et al. | Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study | |
| MX2022010483A (es) | Metodos de tratamiento del complejo de esclerosis tuberosa con cannabidiol y everolimus. | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| MX2021001398A (es) | Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico. | |
| MX2022012692A (es) | Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas. | |
| ATE531366T1 (de) | Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments | |
| BR112023022264A2 (pt) | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo | |
| MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
| CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
| MX2022013904A (es) | Tratamiento de trastornos de adaptacion. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| EA202192928A1 (ru) | Терапевтическое лекарственное средство для лечения дискинезии | |
| Hagerman et al. | Case series: deep brain stimulation in patients with FXTAS | |
| Jeon et al. | A case study of an olfactory disorder in two patients combined by intranasal acupuncture treatment | |
| Naik et al. | Comparative study of acupressure wristband versus palonosetron for prophylaxis of postoperative nausea and vomiting in elective laparoscopic cholecystectomy under general anaesthesia | |
| MX2017014481A (es) | Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la tirosina quinasa. | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
| MX2020002278A (es) | Metodos para el tratamiento de enfermedades relacionadas con tnfa. | |
| CR20220247A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| BR112018016817A2 (pt) | composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento | |
| Eastwood et al. | Hypoglossal nerve stimulation therapy to treat obstructive sleep apnea: interim feasibility trial results | |
| Chen et al. | Clinical study on electroacupuncture for perimenopausal insomnia |